https://orcid.org/0000-0002-3964-7480
References
- Mirzoyev SA, Schrum AG, Davis MDP, et al. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990–2009. J Invest Dermatol. 2014;134(4):1141–1142.
- Seetharam KA. Alopecia areata: an update. Indian J Dermatol Venereol Leprol. 2013;79(5):563–575.
- Giordano CN, Sinha AA. Cytokine pathways and interactions in alopecia areata. Eur J Dermatol. 2013;23(3):308–318.
- Cotellessa C, Peris K, Caracciolo E, et al. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol. 2001;44(1):73–76.
- Gong Y, Zhao Y, Zhang X, et al. Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata. Exp Dermatol. 2020;29(3):231–238.
- Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol. 1983;63(1):49–52.
- Singh G, Lavanya MS. Topical immunotherapy in alopecia areata. Int J Trichol. 2010;2(1):36–39.
- Pan R, Liu J, Xuan X, et al. Chinese experience in the treatment of alopecia areata with diphenylcyclopropenone. J Dermatol. 2015;42(2):220–221.
- Chiang KS, Mesinkovska NA, Piliang MP, et al. Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J Investig Dermatol Symp Proc. 2015;17(2):50–55.
- Salsberg JM, Donovan J. The safety and efficacy of diphencyprone for the treatment of alopecia areata in children. Arch Dermatol. 2012;148(9):1084–1085.
- Aghaei S. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. BMC Dermatol. 2005;5(1):6.
- Lee S, Kim BJ, Lee YB, et al. Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(10):1145–1151.
- Wiseman MC, Shapiro J, MacDonald N, et al. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol. 2001;137(8):1063–1068.
- Sotiriadis D, Patsatsi A, Lazaridou E, et al. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Clin Exp Dermatol. 2006;0(0):060927054804002–060927054804051.
- Gautam RK, Singh Y, Gupta A, et al. The profile of cytokines (IL-2, IFN-γ, IL-4, IL-10, IL-17A, and IL-23) in active alopecia areata. J Cosmet Dermatol. 2020;19(1):234–240.
- Suárez-Fariñas M, Ungar B, Noda S, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol. 2015;136(5):1277–1287.
- Hoffmann R, Wenzel E, Huth A, et al. Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol. 1994;103(4):530–533.
- Lee SH, Moon JH, Ban DH, et al. Can the cytokine analysis of the scales on alopecic patch predict the response to diphenylcyclopropenone treatment in alopecia areata patients? Ann Dermatol. 2018;30(2):150–157.